Galmed Pharmaceuticals Ltd (GLMD)

Currency in USD
4.630
+0.870(+23.14%)
Closed·
4.500-0.130(-2.81%)
·
Unusual trading volume
GLMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.8204.630
52 wk Range
3.28913.200
Key Statistics
Prev. Close
3.825
Open
3.91
Day's Range
3.82-4.63
52 wk Range
3.289-13.2
Volume
264.11K
Average Volume (3m)
60.77K
1-Year Change
-60.2234%
Book Value / Share
15.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Galmed Pharmaceuticals Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000

Earnings

Latest Release
31/08/2026
EPS / Forecast
-2.86 / -3.12
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GLMD Income Statement

Compare GLMD to Peers and Sector

Metrics to compare
GLMD
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.4x−0.4x
PEG Ratio
−0.010.000.00
Price/Book
0.3x1.6x2.6x
Price / LTM Sales
-5.0x3.0x
Upside (Analyst Target)
-593.5%49.7%
Fair Value Upside
Unlock20.6%6.8%Unlock

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
246.000.02%954.48
Other Institutional Investors
42.44K4.24%164.68K
Public Companies & Retail Investors
958.70K95.74%3.72M
Total
1M100.00%3.89M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Heights Capital Management, Inc.2.16%21,66784
Citadel Advisors LLC1.08%10,85642

People Also Watch

2.4400
TNON
-27.38%
4.570
AMIX
-0.22%
2.25
BIYA
-0.44%
1.140
LVWR
-7.32%
4.65
CSAI
-0.21%

FAQ

What Is the Galmed Pharma (GLMD) Stock Price Today?

The Galmed Pharma stock price today is 4.630 USD.

What Stock Exchange Does Galmed Pharma Trade On?

Galmed Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Galmed Pharma?

The stock symbol for Galmed Pharma is "GLMD."

What Is the Galmed Pharma Market Cap?

As of today, Galmed Pharma market cap is 4.600M USD.

What Is Galmed Pharma's Earnings Per Share (TTM)?

The Galmed Pharma EPS (TTM) is -14.106.

When Is the Next Galmed Pharma Earnings Date?

Galmed Pharma will release its next earnings report on 25/11/2026.

From a Technical Analysis Perspective, Is GLMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Galmed Pharma Stock Split?

Galmed Pharma has split 3 times.

How Many Employees Does Galmed Pharma Have?

Galmed Pharma has 5 employees.

What is the current trading status of Galmed Pharma (GLMD)?

As of 09/09/2026, Galmed Pharma (GLMD) is trading at a price of 4.630 USD, with a previous close of 3.825 USD. The stock has fluctuated within a day range of 3.820 USD to 4.630 USD, while its 52-week range spans from 3.289 USD to 13.200 USD.

What Is the GLMD Premarket Price?

GLMD's last pre-market stock price is 3.870 USD. The pre-market share volume is 160,300.000, and the stock has decreased by 0.045, or 1.180%.

What Is the GLMD After Hours Price?

GLMD's last after hours stock price is 4.500 USD, the stock has decreased by -0.130, or -2.810%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.